LoginRegister
    CDSCO directs Veterinary manufacturers to submit Periodic Safety Reports every 6 months for first 2 yearsCDSCO directs Veterinary manufacturers to submit Periodic Safety Reports every 6 months for first 2...
    GAVI to invest USD 178 million for creating Ebola vaccine stockpileGAVI to invest USD 178 million for creating Ebola vaccine stockpile
    Bristol-Myers, bluebird cancer therapy meets goal in mid-stage trialBristol-Myers, bluebird cancer therapy meets goal in mid-stage trial
    Bayer, plaintiffs to postpone more glyphosate lawsuits for settlement talksBayer, plaintiffs to postpone more glyphosate lawsuits for settlement talks
    Govt action against BioMed contaminated polio vaccine supply; Minister informs RSGovt action against BioMed contaminated polio vaccine supply; Minister informs RS
    Dabur eyes to acquire firms, expand in rural India with Rs 3500 crore war chest: ReportDabur eyes to acquire firms, expand in rural India with Rs 3500 crore war chest: Report
    Generic versions of Novartis blockbuster MS drug Gilenya gets USFDA green flagGeneric versions of Novartis blockbuster MS drug Gilenya gets USFDA green flag
    AstraZeneca-Merck cancer drug Lynparza wins approval in ChinaAstraZeneca-Merck cancer drug Lynparza wins approval in China
    GSK seeks USFDA approval for investigational HIV treatment FostemsavirGSK seeks USFDA approval for investigational HIV treatment Fostemsavir
    Enzyvant regenerative therapy for rare immune disorder rejected by USFDA over manufacturing concernsEnzyvant regenerative therapy for rare immune disorder rejected by USFDA over manufacturing concerns
    UCB psoriasis drug Bimekizumab beats AbbVie blockbuster Humira in late-stage trialUCB psoriasis drug Bimekizumab beats AbbVie blockbuster Humira in late-stage trial
    Dr Reddys launches generic version of Hemabate injection indicated for abortion in USDr Reddys launches generic version of Hemabate injection indicated for abortion in US
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X